The role of the kidneys in glucose homeostasis: A new path towards normalizing glycaemia

Diabetes, Obesity and Metabolism

Volumn 14, Issue 1, 2012, Pages 5-14

  DeFronzo, R A ^a,b   Davidson, J A ^c,e   del Prato, S ^d  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF PISA   (Italy)

^e Worldwide Initiative for Diabetes Education   (United States)

Author keywords

Clinical trials; Diabetes; Glucose homeostasis; Glycosuria; Hyperglycaemia; Kidneys; Renal glucose transport; SGLT2; SGLT2 inhibitors; Sodium glucose cotransporters

Indexed keywords

ANTIDIABETIC AGENT; AVE 2268; CANAGLIFLOZIN; CSG 452A; DAPAGLIFLOZIN; EMPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; ISIS 388626; METFORMIN; PHLORIZIN; PLACEBO; REMOGLIFLOZIN ETABONATE; SAR 7226; SERGLIFLOZIN ETABONATE; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TS 033; UNCLASSIFIED DRUG; YM 543;

CELL FUNCTION; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; GENITAL TRACT INFECTION; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSURIA; HEMATOCRIT BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; KIDNEY FUNCTION; KIDNEY PROXIMAL TUBULE; LIVER; MAGNESIUM BLOOD LEVEL; MUSCLE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS FUNCTION; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; SIDE EFFECT; STREPTOZOCIN DIABETES; URIC ACID BLOOD LEVEL; URINARY TRACT INFECTION; URINE VOLUME;

EID: 83655193529     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01511.x     Document Type: Review

References (76)

1. DeFronzo RA. The triumvirate: beta-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 1988; 37: 667-687.
2. Kahn SE, Zraika S, Utzschneider RL, Hull RL. The beta cell lesion in type 2 diabetes: there has to be a primary functional abnormality. Diabetologia 2009; 52: 1003-1012.
3. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002; 32(Suppl. 3): 14-23.
4. DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773-795.
5. Mitrakou A, Kelley D, Veneman T et al. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycaemia in NIDDM. Diabetes 1990; 39: 1381-1390.
6. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev 1999; 20: 876-913.
7. Kashyap S, Belfort R, Gastaldelli A et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 2003; 52: 2461-2474.
8. DeFronzo RA, Mandarino LJ. Pathogenesis of type 2 diabetes mellitus. In: Goldfine ID, Rushakoff RJ eds. Diabetes and Carbohydrate Metabolism. Available from URL: Accessed 2 March 2003.
9. Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 2006; 29: 1130-1139.
10. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 26: 2929-2940.
11. Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med 2007; 261: 32-43.
12. Abdul-Ghani MA, DeFronzo RA. Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. EndocrPract 2008; 14: 782-790.
13. Vallon V, Platt KA, Cunard R et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 2011; 22: 104-112.
14. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev 2011; 91: 733-794.
15. Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005; 54: 3427-3434.
16. United Kingdom Prospective Study Group. U.K. prospective study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes.1995; 44: 1249-1258. Diabetes.
17. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-2012.
18. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
19. Diabetes Atlas Committee. Diabetes Atlas, 3rd edn. Brussels: International Diabetes Federation, 2007.
20. American Association of Clinical Endocrinologists. State of diabetes complications in America. Blood sugar levels. Available from URL: Accessed 2 March 2009.
21. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care 2008; 31: 81-86.
22. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. UKPDS 80. N Engl J Med 2008; 359: 1565-1576.
23. Gerstein HC, Miller ME, Byington RD et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
24. Patel A, MacMahon S, Chalmers J et al. for the ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
25. Duckworth W, Abraira C, Moritz T et al. for the VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
26. Del Prato S. Megatrials in type 2 diabetes. From excitement to frustration? Diabetologia 2009; 52: 1219-1226.
27. Dominguez JH, Song B, Maianu L, Garvey WT, Qulali M. Gene expression of epithelial glucose transporters: the role of diabetes mellitus. J Am SocNephrol 1994; 5(Suppl. 1): S29-S36.
28. Hediger MA, Rhoads DB. Molecular physiology of sodium-glucose cotransporters. Physiol Rev 1994; 74: 993-1026.
29. Valtin H. Renal function: mechanism preserving fluid and solute balance in health. Boston: Little, Brown, and Company, 1983.
30. Farber SJ, Berger EY, Earle DP. Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest 1951; 30: 125-129.
31. Mogensen CE. Maximum tubular reabsorption capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest 1971; 28: 101-109.
32. Dominguez JH, Camp K, Maianu L, Feister H, Garvey WT. Molecular adaptations of GLUT1 and GLUT2 in renal proximal tubules of diabetic rats. Am J Physiol 1994; 266(2, Pt 2): F283-F290.
33. Kamran M, Peterson RG, Dominguez JH. Over-expression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats. J Am SocNephrol 1997; 8: 943-948.
34. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care 1990; 13: 610-630.
35. Kahn BB, Rossetti L, Lodish HF, Charron MJ. Decreased in vivo glucose uptake but normal expression of GLUT1 and GLUT4 in skeletal muscle of diabetic rats. J Clin Invest 1991; 87: 2197-2206.
36. Mevorach M, Giacca A, Aharon Y, Hawkins M, Shamoon H, Rossetti L. Regulation of endogenous glucose production by glucose per se is impaired in type 2 diabetes mellitus. J Clin Invest 1998; 102: 744-753.
37. Oku A, Ueta K, Arakawa K et al. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 1999; 48: 1794-1800.
38. Kosaka K, Kuzuya T, Akanuma Y, Hagura R. Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment. Diabetologia 1980; 18: 23-28.
39. Yki-Jarvinen H. Glucose toxicity. Endocr Rev 1992; 13: 415-431.
40. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987; 79: 1510-1515.
41. Lisato G, Cusin I, Tiengo A, Del Prato S, Jeanrenaud B. The contribution of hyperglycaemia and hypoinsulinaemia to the insulin resistance of streptozotocin-diabetic rats. Diabetologia 1992; 35: 310-315.
42. Rossetti L, Shulman GI, Zawalich W, DeFronzo RA. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest 1987; 80: 1037-1044.
43. Starke A, Grundy S, McGarry JD, Unger RH. Correction of hyperglycemia with phloridzin restores the glucagon response to glucose in insulin-deficient dogs: implications for human diabetes. Proc Natl Acad Sci U S A 1985; 82: 1544-1546.
44. +/glucose cotransporter as molecular targets of anti-diabetic drugs. Curr Med Chem 2004; 11: 2717-2724.
45. Nunoi K, Yasuda K, Adachi T et al. Beneficial effect of T-1095, a selective inhibitor of renal Na+-glucose cotransporters, on metabolic index and insulin secretion in spontaneously diabetic GK rats. Clin Exp Pharmacol Physiol 2002; 29: 386-390.
46. Han S, Hagan DL, Taylor JR et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008; 57: 1723-1729.
47. MacDonald RF, Westgate L, Poucher SM, Mayers RM, Whaley JM. The SGLT2 inhibitor dapagliflozin prevents the loss of pancreatic function in the high fat fed female (HFFF) ZDF rat (Abstract 1468-P). Diabetes 2009; 58(Suppl. 2).
48. Liang Y, Arakawa K, Martin T et al. JNJ-28431754/TA-7284, an SGLT2 inhibitor, lowers blood glucose and reduces body weight in obese and type 2 diabetic animal models (Abstract 534-P). Diabetes 2009; 58(Suppl. 2).
49. Grempler R, Thomas L, Eckhardt M et al. In vitro properties and in vivo effect on urinary glucose excretion of BI 10773, a novel selective SGLT2 inhibitor (Abstract 521-P). Diabetes 2009; 58(Suppl. 2).
50. Wancewicz EV, Siwkowski A, Meibohm B et al. Long term safety and efficacy of ISIS 388626, an optimized SGLT2 antisense inhibitor, in multiple diabetic and euglycemic species (Abstract 334-OR). Diabetes 2008; 57(Suppl. 2).
51. Bhanot S, Murray SF, Booten SL et al. ISIS 388626, an SGLT2 antisense drug, causes robust and sustained glucosuriaglycosuria in multiple species and is safe andwell-tolerated (Abstract 328-P). Diabetes 2009; 58(Suppl. 2).
52. Santer R, Calado J. Familial renal glucosuria and SLGT2: from a mendelian trait to a therapeutic target. Clin J Am SocNephrol 2010; 5: 133-141.
53. Santer R, Kinner M, Lassen CL et al. Molecular analysis of the SGLT2 gene in patients with renal glycosuria. J Am SocNephrol 2003; 14: 2873-2882.
54. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009; 85: 513-519.
55. Meng W, Ellsworth BA, Nirschl AA et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008; 51: 1145-1149.
56. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose co-transport inhibition with dapagliflozin in type 2 diabetes mellitus. Diabetes Care 2009; 32: 650-657.
57. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 2223-2233.
58. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozinmonotherapy in type 2 patient with diabetess with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010; 33: 2217-2224.
59. Nauck M, Del Prato S, Rohwedder K, Elze M, Parikh S. Dapagliflozinvsglipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin: 52-week results of a double-blind, randomised, controlled trial. Diabetologia 2010; 53(Suppl. 1): S1-S556.
60. Wilding JP, Norwood P, T'Joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 2009; 32: 1656-1662.
61. Zhang L, Feng Y, List J, Kasichayanula S, Pfister M. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab 2010; 12: 510-516.
62. Wilding JPH, Norwood P, T'Joen C, Bastien A, List JF, Fiedorek FT. Dapagliflozin pilot study in insulin-resistant T2DM patients (Abstract 482-P). Diabetes 2009; 58(Suppl. 2).
63. Hussey E, Clark R, Amin M et al. Early clinical studies to assess safety, tolerability, pharmacokinetics and pharmacodynamics of single dose of sergliflozin, a novel inhibitor of renal glucose reabsorption in healthy volunteers and subjects with type 2 diabetes mellitus. Diabetes 2007; 56(Suppl. 1): A189.
64. Hussey E, Dobbins R, Stolz R et al. A double-blind randomized repeat dose study to assess safety, tolerability, pharmacokineticks and pharmacodynamics of three times daily dosing of sergliflozin, a novel inhibitor of renal glucose reabsorption in healthy overweight and obese subjects. Diabetes 2007; 56(Suppl. 1): A491.
65. Rosenstock J, Arbit D, Usiskin K, Capuano G, Canovatchel W. Canagliflozin an inhibitor of sodium glucose co-transporter 2 (SGLT2), improves glycemic control and lowers body weight in subjects with type 2 diabetes (T2D) on metformin. Diabetes 2010; 59(Suppl. 1): A21.
66. Polidori D, Zhao Y, Sha S, Canovatchel W. Canagliflozin treatment improves beta cell function in subject with type 2 diabetes. Diabetes 2010; 59(Suppl. 1): A176.
67. Schwartz S, Morrow L, Hompesch M et al. Canagliflozin improves glycemic control in subjects with type 2 diabetes (T2D) not optimally controlled on stable doses of insulin. Diabetes 2010; 59(Suppl. 1): A154.
68. Koiwai K, Seman L, Yamamura N et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of BI 10773, a sodium-glucose co-transporter inhibitor (SGLT2), in Japanese healthy volunteers. Diabetes 2010; 59(Suppl. 1): A571.
69. Kashiwagi A, Utsuno A, Kazuta K, Yoshida S, Kageyama S. ASP1941, a novel, selective SGLT2 inhibitor, was effective and safe in Japanese healthy volunteers and patients with type 2 diabetes mellitus. Diabetes 2010; 59(Suppl. 1): A21.
70. Freiman J, Ruff DA, Frazier KS et al. LX4211, a dual SGLT2/SGLT1 inhibitor, shows rapid and significant improvements in glycemic control over 28 days in patients with type 2 diabetes (T2DM). Diabetes 2010; 59(Supp. 1): 17-LB.
71. Bickel M, Brummerhop H, Frick W et al. Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats. Arzneimittelforschung 2008; 58: 574-580.
72. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
73. United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
74. Bank N, Aynedjian HS. Progressive increases in luminal glucose stimulate proximal sodium absorption in normal and diabetic rats. J Clin Invest 1990; 86: 309-316.
75. Nelson RG, Bennett PH, Beck GJ et al. for The Diabetic Renal Disease Study Group. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. N Engl J Med 1996; 335: 1636-1642.
76. Tuttle KR, Bruton JL, Perusek MC, Lancaster JL, Kopp DT, DeFronzo RA. Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus. N Engl J Med 1991; 324: 1626-1632.